A5101989171- Acute Myeloid Leukemia Research
- Lymphoma Diagnosis and Treatment
- Histone Deacetylase Inhibitors Research
- Protein Degradation and Inhibitors
- Chronic Lymphocytic Leukemia Research
- Immune Cell Function and Interaction
- Chronic Myeloid Leukemia Treatments
- Acute Lymphoblastic Leukemia research
- CAR-T cell therapy research
- Viral-associated cancers and disorders
- Cancer-related molecular mechanisms research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Retinoids in leukemia and cellular processes
- RNA Research and Splicing
- Ovarian cancer diagnosis and treatment
- Genomics and Chromatin Dynamics
- Single-cell and spatial transcriptomics
- Multiple Myeloma Research and Treatments
- Autophagy in Disease and Therapy
- Phagocytosis and Immune Regulation
- Ubiquitin and proteasome pathways
- Genomics, phytochemicals, and oxidative stress
- T-cell and B-cell Immunology
- Cancer-related gene regulation
- Natural Compounds in Disease Treatment
First Affiliated Hospital of Xiamen University
2016-2025
Xiamen University
2018-2024
Anqing Normal University
2024
Fujian Medical University
2023
University of Florida
2018-2022
Penn State Milton S. Hershey Medical Center
2022
Florida College
2018-2022
Pennsylvania State University
2022
Southern Medical University
2012-2014
Nanfang Hospital
2012-2014
Abstract Acute myeloid leukemia (AML) is a heterogeneous malignancy. Despite the advances in past decades, clinical outcomes of AML patients remain poor. Leukemia stem cells (LSCs) major cause recurrence even after aggressive treatment making, promoting development LSC-targeted agents an urgent need. Although antitumor activity disulfiram (DS), approved anti-alcoholism drug, has been demonstrated multiple types tumors including hematological malignancies such as AML, it remains unknown...
Disulfiram (DS), an anti-alcoholism drug, demonstrates strong antitumor activity in a copper (Cu)-dependent manner. This study investigates the cytotoxicity of DS/Cu complex lymphoid malignant cell lines vitro and vivo. Raji cells were subjected to different treatments thereafter MTT assay, flow cytometry used determine IC50 apoptotic status. We also tested acute lymphoblastic leukemia line Molt4 vitro. In vivo experiments performed demonstrate anticancer efficacy xenografted nude mice....
Introduction Despite accumulated evidence in T-cell exhaustion acute myeloid leukemia (AML), the immunotherapeutic targeting exhausted T cells such as programmed cell death protein 1 (PD-1) blockade AML failed to achieve satisfying efficacy. Characteristics of remained be explored. Methods Phenotypic analysis bone marrow (BM) using flow cytometry combining senescent and markers was performed de novo patients healthy donors well with complete remission (CR). Functional subsets also cytometry....
Abstract While the aberrant translocation of mixed-lineage leukemia (MLL) gene drives pathogenesis acute myeloid (AML), it represents an independent predictor for poor prognosis adult AML patients. Thus, small molecule inhibitors targeting menin-MLL fusion protein interaction have been emerging treatment MLL-rearranged AML. As both histone deacetylase (HDAC) and target transcription-regulatory machinery involving epigenetic regulation chromatin remodeling that governs expression genes...
Patients with follicular lymphoma (FL) who experience progression of disease within 24 months (POD24) receiving first-line therapy had a significantly poorer prognosis than that without early progression. Due to the established prognostic relevance positron emission tomography/computed tomography (PET/CT) parameters in FL and their clinical accessibility, we aimed investigate predictive role PET/CT metabolism dissemination POD24 for FL. The status 155 patients underwent examinations at...
Acute myeloid leukemia (AML) is a heterogeneous neoplasm with poor clinical outcome, despite the great progress in treatment recent years. The selective Bcl-2 inhibitor venetoclax (ABT-199) combination therapy has been approved for of newly diagnosed AML patients who are ineligible intensive chemotherapy, but resistance can be acquired through upregulation alternative antiapoptotic proteins. Here, we reported that emerged histone deacetylase inhibitor, chidamide (CS055), at low-cytotoxicity...
The difference between clinical characteristics and outcomes follicular lymphoma grade 1-2 (FL1-2) FL3a defined pathologically remains unclear, resulting in uncertainty how to treat FL3a. However, it may be crucial for clinicians discriminate 3a predicting prognosis thus making treatment decisions.
Acute lymphoblastic leukemia (ALL) is a clonal malignant disorder characterized by an uncontrolled proliferation of immature B or T lymphocytes. Extensive studies have suggested involvement angiogenesis signaling in ALL progression and resistance to treatment. Thus, targeting with anti-angiogenic drugs may be promising approach for In this study, we investigated the effectiveness Apatinib, novel receptor tyrosine kinase inhibitor selectively VEGFR-2 cells. cell lines were treated different...
Group 2 innate lymphoid cells (ILC2s) are critical sources of type cytokines and represent one the major tissue-resident in mouse lung. However, molecular mechanisms underlying ILC2 activation under challenges not fully understood.Here, using single-cell transcriptomics, genetic reporters, gene knockouts, we identify four subsets, including two non-activation subsets acute inflammatory Of note, a distinct subset, marked by transcription factor Nr4a1, paradoxically expresses both memory T...
Immunotherapy using PD-L1 blockade is effective in only a small group of cancer patients, and resistance common. This emphasizes the importance understanding mechanisms immune evasion resistance. A genome-scale CRISPR-Cas9 screen identified Bap1 as regulator expression. To measure tumor size survival, cells were subcutaneously injected into both syngeneic WT mice immunocompromised mice. The phenotypic transcriptional characteristics Bap1-deleted tumors examined flow cytometry, RNA-seq,...
To investigate the combined action of decitabine (DAC) with chidamide (CS055) on acute lymphoblastic leukemia (ALL) cells.ALL cell lines as well primary cells from 17 ALL patients were subjected to different treatments and thereafter counting Kit-8 (CCK-8) assay, flow cytometry western blot employed determine IC50, apoptosis checkpoint kinase 1 γH2A.X expression.Low-dose DAC CS055 could effectively kill by reduction viability induction apoptosis. This was also observed in patients,...
Abstract Refractory or relapsed (R/R) AML is the most challenging form of to treat. Due frequent genetic mutations, therapy alternatives are limited. Here, we identified role ritanserin and its target DGKα in AML. Several cell lines primary patient cells were treated with subjected proliferation, apoptosis gene analyses CCK-8 assay, Annexin V/PI assay Western blotting, respectively. We also evaluated function diacylglycerol kinase alpha (DGKα) by bioinformatics. In vitro experiments have...